Siemens Healthineers (OTCMKTS:SMMNY) Rating Increased to Hold at Zacks Research

Siemens Healthineers (OTCMKTS:SMMNY) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Thursday,Zacks.com reports.

Siemens Healthineers Price Performance

Shares of SMMNY opened at $22.81 on Thursday. The business’s 50 day moving average price is $20.20 and its 200-day moving average price is $21.66. Siemens Healthineers has a 52 week low of $19.20 and a 52 week high of $28.92.

Siemens Healthineers (OTCMKTS:SMMNY) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.02. The company had revenue of $6.68 billion for the quarter, compared to analysts’ expectations of $6.96 billion.

About Siemens Healthineers

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.

The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.